For the year ending 2025-12-31, LYEL made $36K in revenue. -$274,497K in net income. Net profit margin of -762491.67%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 36 | |||
| Research and development | 158,675 | |||
| General and administrative | 45,135 | |||
| Other operating income, net | 2,145 | |||
| Acquired in-process research and development | 66,332 | |||
| Impairment of long-lived assets | 1,443 | |||
| Total operating expenses | 269,440 | |||
| Loss from operations | -269,404 | |||
| Interest income, net | 13,080 | |||
| Other (expense) income, net | -18,124 | |||
| Impairment of other investments | 0 | |||
| Total other (loss) income, net | -5,044 | |||
| Net loss | -274,448 | |||
| Net unrealized (loss) gain on marketable securities | -49 | |||
| Comprehensive loss | -274,497 | |||
| Basic EPS | -16.06 | |||
| Diluted EPS | -16.06 | |||
| Basic Average Shares | 17,093,000 | |||
| Diluted Average Shares | 17,093,000 | |||
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)